11,716 Results
Phase III INCREASE study of Tyvaso meets primary endpoint in pulmonary hypertension with interstitial lung disease.- United Therapeutics
Added 18 hours ago
United Therapeutics announced that preliminary analysis indicates that the phase III INCREASE clinical study of Tyvaso (treprostinil) Inhalation Solution in...
FDA and EMA accept filings of subcutaneous ofatumumab for the treatment of relapsing Multiple Sclerosis.- Genmab A/S + Novartis
Added 18 hours ago
Genmab A/S announced that the FDA has accepted, with priority review, the supplemental Biologics License Application (sBLA) submitted by Novartis...
FDA accepts NDA for Libervant Buccal Film for the treatment of seizure clusters. -Aquestive Therapeutics.
Added 1 day ago
Aquestive Therapeutics, Inc. announced that, as anticipated, the FDA accepted the Company’s New Drug Application (NDA) for Libervant (diazepam) Buccal...
FDA approves Trulicity to reduce major adverse cardiovascular events in type 2 diabetes patients Eli Lilly
Added 2 days ago
The FDA has approved Trulicity (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2...
FDA approves Nexletol to treat heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease - Esperion.
Added 2 days ago
Esperion has announced that the FDA approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. Nexletol...
FDA approves Anjeso to treat moderate to severe pain.- Baudax Bio
Added 2 days ago
Baudax Bio, Inc. announced that the FDA has approved the New Drug Application (NDA) for Anjeso (meloxicam injection), which is...
Interim data from the SIERRA trial of Iomab-B shows side effect differences in Acute Myeloid Leukemia patients.- Actinium Pharma
Added 2 days ago
Actinium Pharmaceuticals announced findings from the SIERRA trial of Iomab-B (monoclonal antibody BC8 / I-131) in Elderly Relapse/Refractory Acute Myeloid...
FDA approves Vyepti for migraine prevention.- Lundbeck
Added 2 days ago
Lundbeck has announced that Vyepti (eptinezumab-jjmr) has been approved by the FDA for the preventive treatment of migraine in adults...
Teva Pharmaceutical Industries Ltd. announced deutetrabenazine failed to meet the endpoint in in Phase II/III trials to treat tics in pediatric patients with Tourette Syndrome.
Added 3 days ago
Teva Pharmaceutical Industries Ltd. announced the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials designed to evaluate deutetrabenazine...
Tocagen and Forte Biosciences to merge.
Added 3 days ago
Tocagen Inc. and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of...